Timothy August Durso - 03 Feb 2026 Form 4 Insider Report for Veradermics, Inc (MANE)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
4
Accepted by SEC
05 Feb 2026, 19:00:50 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Michael Greco, Attorney-in-Fact

Key filing fact

Timothy August Durso filed Form 4 for Veradermics, Inc (MANE) on 05 Feb 2026.

Key facts

  • This page summarizes Timothy August Durso's Form 4 filing for Veradermics, Inc (MANE).
  • 3 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 05 Feb 2026, 19:00.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002107508 Primary reporting owner

Durso Timothy August

Relationship
Chief Technical Officer
Address
C/O VERADERMICS, INCORPORATED, 470 JAMES ST., NEW HAVEN
Signature
/s/ Michael Greco, Attorney-in-Fact
Signature date
05 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MANE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+1,473
Change %
+1.3%
Price
Shares after
118,190
Date
05 Feb 2026
Ownership
Direct
Footnotes
F1
MANE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
116,717
Date
03 Feb 2026
Ownership
By Durso Family Trust
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MANE transaction Derivative

Series A Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares
-1,473
Change %
-100%
Price
Shares after
0
Date
05 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,473
Exercise price
Footnotes
F1
MANE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+213,352
Change %
Price
$0.000000
Shares after
213,352
Date
03 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
213,352
Exercise price
$17.00
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share (the "Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

Footnote F2

These shares are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Footnote F3

The option vests as to 25% of the underlying shares of Common Stock on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .